Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 12, 2022

Palbociclib Rechallenge for HR+/HER2− Advanced Breast Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Clin. Cancer Res 2022 Sep 27;[EPub Ahead of Print], J Albanell, JM Peréz-García, M Gil-Gil, G Curigliano, M Ruíz Borrego, L Comerma, J Gibert, M Bellet, B Bermejo, L Calvo, J de la Haba, E Espinosa, AMM Minisini, V Quiroga, A Santaballa Bertran, L Mina, B Bellosillo, F Rojo, S Menéndez, M Sampayo-Cordero, C Popa, A Malfettone, J Cortés, A Llombart-Cussac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading